Markets

Cempra Antibiotic Meets Endpoints, Adverse Events Concerning

A generic image of a person on their smartphone
Credit: Shutterstock photo

Cempra, Inc.CEMP announced positive top-line results from a global, phase III study (Solitaire-IV) on pipeline candidate intravenous (IV) to oral solithromycin. Cempra is evaluating solithromycin for the treatment of community-acquired bacterial pneumonia (CABP).

In the study, solithromycin met the primary objective of statistical non-inferiority compared to moxifloxacin at the early clinical response in the intent-to-treat population. The point estimates for early clinical response were 79.3% for solithromycin and 79.7% for moxifloxacin.

Solithromycin also met the co-primary objective of statistical non-inferiority compared to moxifloxacin at the early clinical response in the microbiological intent-to-treat population from the pooled data from both phase III studies.

The FDA has granted Fast Track designation and Qualified Infectious Disease Product (QIDP) status to solithromycin (IV and capsules) for the treatment of CABP. The agency has also designated solithromycin capsules for the treatment of gonorrhea as QIDP.

Based on encouraging phase III study data, the company plans to start submitting a rolling new drug application for solithromycin for the treatment of CABP by the end of this year and complete the submission by the first half of 2016.

However, treatment-related adverse events were higher in the solithromycin (34.3%) arm as compared to moxifloxacin (13.1%).

Going forward, we expect investor focus on further pipeline updates as Cempra does not have any approved product in its portfolio. Currently, the CABP market has the presence of companies like Pfizer PFE , Allergan AGN and Bayer BAYRY .

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BAYER A G -ADR (BAYRY): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

ALLERGAN PLC (AGN): Free Stock Analysis Report

CEMPRA INC (CEMP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BAYRY PFE

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More